BioInformant

Your Global Leader in Stem Cell Market Research

Home » cynata » Page 3

Cynata Therapeutics Lands Japanese Giant Fujifilm

By

Cynata TherapeuticsIt is not every day that an Aussie minnow lands a deal with a Japanese whale. When Fujifilm took a 9% equity stake in Cynata Therapeutics Ltd (ASX: CYP), it was a major lift for the regenerative medicine company, positioning Cynata to benefit not only from Fujifilm’s resources but also more broadly from current economic strategy within Japan.

Prime Minister of Japan, Shinzō Abe, has committed to building leadership around a new generation of regenerative medicine products involving human cells and tissues and Cynata is now perfectly positioned to take advantage of this in the world’s second largest market for healthcare products. [Read more…]

Dr Paul Wotton appointed as Chairman of the Cynata Board

By

Cynata TherapeuticsMelbourne, Australia; 28 February 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP) is pleased to announce the appointment of existing nonexecutive director Dr Paul Wotton as Chairman of the Board of Directors. With Cynata now transitioning to a clinical stage company, the Board believes that Dr Wotton has the skills, focus and proven track record to help steer the Company effectively through this next stage of growth. Past chairman Dr Stewart Washer will remain on the Board as a non-executive Director. [Read more…]

Cynata Advances Development of Cymerus™ MSCs for the Treatment of Asthma

By

  • Final report of initial preclinical study confirms Cymerus™ MSCs have significant beneficial effects on all three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling
  • Additional preclinical study expected to pave the way for a potential clinical trial

Cynata TherapeuticsMelbourne, Australia; 2 March 2017 – Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has signed an agreement with the Monash Lung Biology Network, a consortia involving researchers from the Monash Biomedicine Discovery Institute and Department of Pharmacology at Monash University, Melbourne, to conduct a further preclinical study to support the use of CymerusTM mesenchymal stem cells (MSCs) for the treatment of asthma. [Read more…]

Treatment Benefit Confirmed in Final Report of GvHD Preclinical Study Using Cynata’s MSCs

By

  • Robust survival benefit resulting from treatment with CYP-001 confirmed

  • Substantial body of data generated to support mechanism of action of CYP-001 in GvHD

Cynata TherapeuticsMelbourne, Australia; 6 February 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has received a final report of the proof of concept study of its lead CymerusTM mesenchymal stem cell (MSC) product for graft-versus-host disease (GvHD), CYP-001, in a humanised mouse model of GvHD, which was conducted under the supervision of Associate Professor Lisa Minter at the University of Massachusetts Amherst (UMass), USA. [Read more…]

Cynata Therapeutics Secures $6M in Capital Raise, $10M with Payment from FUJIFILM

By

Cynata Successfully Completes Capital Raising

Cynata TherapeuticsMelbourne, Australia; 23 January 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has successfully completed a placement of approximately 9.23 million fully-paid ordinary shares at a price of $0.65, for gross proceeds of A$6.0 million before costs (“Placement”). The Placement was made to existing and new sophisticated and institutional investors. Settlement of the Placement, which was heavily over-subscribed, is expected to occur on or about 27 January 2017 with the shares to be issued on 30 January 2017. The Placement shares will be issued under Cynata’s existing placement capacity under Listing Rules 7.1 and 7.1A, and accordingly will not require shareholder approval.  [Read more…]

BioInformant's World-Class Clients